- 专利标题： 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS
-
申请号： US16315930申请日： 2017-07-10
-
公开(公告)号： US20200181089A1公开(公告)日： 2020-06-11
- 发明人: Thierry PASSERON , Rachid BENHIDA , Pascal DAO , Gian Marco DE DONATIS , Anthony MARTIN
- 申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , CHU DE NICE
- 优先权： com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@473d74ed
- 国际申请： PCT/EP2017/067306 WO 20170710
- 主分类号： C07D215/44
- IPC分类号： C07D215/44 ; C07D413/04 ; C07D401/04 ; C07D405/04 ; A61P35/04
摘要：
The present invention relates to a compound of general formula (I): said compound being as defined in claim (1). The invention also relates to a pharmaceutical composition comprising: —a compound of general formula (I) as defined in claim (12) and, —at least one antibody selected from an anti-PD1 antibody, an anti-CTLA4 antibody, an anti-PD-L1 antibody and a mixture of two or more thereof. The invention also relates to a compound of general formula (I) as defined in claim (17) for use in the treatment of cancer, said cancer being preferably selected from melanoma, bladder, kidney, prostate, colon, lung, breast and blood cancer.
信息查询
